Protalix (PLX) Director Eliot Forster Receives RSU Awards

What Happened

• Eliot Forster, a director of Protalix BioTherapeutics (PLX), received two equity awards on September 3, 2026: 17,000 and 8,500 shares reported as derivative grants (total 25,500). Each grant shows a $0.00 acquisition price (no cash paid) and is reported as an award/derivative transaction.

Key Details

• Transaction date: 2026-09-03; Form 4 filed: 2026-09-04 (timely).
• Grant details: 17,000 and 8,500 RSU-style awards (total 25,500); acquisition price reported $0.00.
• Vesting: The awards vest in 12 equal quarterly installments commencing on the grant date (i.e., quarterly over 3 years) per filing footnotes.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Other holdings noted: filing excludes previously held options — 85,715 options at $1.75 exp. 9/14/2033 and 15,000 options at $1.64 exp. 9/3/2035.
• No 10b5-1 plan, tax-withholding sale, or late filing indicated in this submission.

Context

• These appear to be restricted stock units (RSUs): each RSU represents the right to receive one share upon vesting, so no shares were delivered immediately and no cash was paid. Awards that vest over time are common compensation for directors and do not by themselves indicate a buy or sell signal.